Skip to main content
Conference Coverage

Medicaid Coverage Alone May Not Increase Access to Obesity Medications

Key Takeaways:

  • In 2023, Pennsylvania (PA) and Delaware (DE) introduced new Medicaid coverage for obesity management medications (OMMs), which were intended to improve access among patients with obesity.
  • Researchers compared OMM prescribing rates before and after policy changes in both PA and DE and against New Jersey (NJ), which did not implement new coverage.
  • Base and adjusted analyses did not find a significantly meaningful association between Medicaid coverage and OMM prescriptions, highlighting the need for additional research.

At ObesityWeek 2026, researchers presented their findings from a study assessing the impact of Medicaid OMM coverage on treatment patterns.

While therapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual agonists have demonstrated significant effectiveness in disease management, their high costs lead few payers to offer coverage. However, both PA and DE implemented coverage policies for several obesity medications in 2023.

Study Methods and Outcomes

Researchers used data from HealthShare Exchange (HSX) to observe the effect of state Medicaid coverage on treatment patterns.

The study included 105 178 unique patients across Southeastern PA, Northern DE, and Southern NJ with at least 1 outpatient visit between 2021 and 2024.

A difference-in-differences (DiD) analysis was conducted to compare treatment rates before and after policy changes in states that introduced coverage (PA and DE) against states that did not (NJ).

Medicaid Coverage Has No Significant Impact on Treatment Patterns

Base DiD estimates found that patients in PA and DE were 11% more likely to be prescribed OMMs after new policies were implemented compared to those in NJ. After adjustments, however, these odds decreased to 7%. Neither increase was significantly meaningful.

Implications for Managed Care

Increased Medicaid coverage was not significantly associated with increases in OMM prescriptions among patients with obesity, indicating that the policy changes had little impact on treatment patterns.

The authors suggest these findings could reflect additional access barriers beyond coverage, including OMM supply issues and stigmas surrounding weight and obesity medications. Study limitations such as sampling, data imprecision, or cross-diagnostics for incretin-based therapy may also have affected the results.

Further research on the impacts of OMM coverage as well as strategies to improve medication access may be beneficial for patients with obesity.

Reference

Schumacher LM, Hannah J, Dzomba B, Yucel R. Impact of Medicaid coverage for obesity management medications on prescribing patterns. Poster 643. Abstract presented at: ObesityWeek 2026; November 14-17, 2026; Washington, DC.